Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Adcendo.

    Client Virtual Booth

    ADCENDO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Adcendo
    Denmark Flag
    Country
    Country
    Denmark
    Address
    Address
    BioInnovation Institute, Ole Maaløes Vej 3, Copenhagen, Capital Region of Denmark 2200
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://adcendo.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/adcendo/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline

    Details:

    Under the agreement, new targets will be evaluated with Duality’s linker-payload platform, designed to generate ADCs with superior safety profiles, sustainable payload delivery and release in tumors, and efficient bystander killing of antigen low and negative cells.


    Lead Product(s): Antibody-drug Conjugate

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Recipient: Duality Biologics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement May 30, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline

    Details:

    Adcendo intends to use the proceeds from the financing to initiate a broad clinical development program for uPARAP Antibody Drug Conjugate in Sarcoma and is also planning to advance the development of its 2nd ADC pipeline asset.


    Lead Product(s): Antibody Drug Conjugate

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Pontifax Venture Capital

    Deal Size: $89.5 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing April 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

    Details:

    Antibody Drug Conjugates (ADC) are a class of highly potent biopharmaceutical drug composed of a targeting antibody linked to a biologically active drug or cytotoxic compound. uPARAP is a novel cancer target overexpressed on the cell surface of mesenchymal cancers.


    Lead Product(s): Antibody-drug Conjugate-based Therapy

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Recipient: Duality Biologics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novo Seeds Co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

    Details:

    The new financing, which is the largest Series A financing for a Danish biotech company to develop Antibody drug conjugate, will be used to establish a pipeline of ADCs directed at novel cancer targets and to bring the lead program targeting uPARAP/Endo180.


    Lead Product(s): Antibody drug conjugate

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Novo Seeds

    Deal Size: $62.2 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing April 29, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search